Healthcare / Drug Manufacturers - Specialty & GenericBSE
$35.06
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $25.3M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$273M
P/E
N/A
•EV/EBITDA
6.6x
↓ROE
-15.1%
↓Gross Margin
61.7%
↑Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.7%
FCF CAGR
—
FCF margin
6.1%
FCF / Net income
-3.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $502.0M · net income $-9.8M · FCF $30.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $502.0M | $502.0M | $479.7M | $467.8M | $401.3M |
| Net Income | $-9.8M | $-9.8M | $2.4M | $-16.7M | $8.7M |
| EBITDA | $41.4M | $41.4M | $15.4M | $-18.6M | $13.6M |
| EPS | -1.32 | -1.32 | 0.33 | -2.25 | 1.18 |
| Gross Margin | 61.7% | 61.7% | 62.8% | 57.8% | 60.9% |
| Operating Margin | 7.0% | 7.0% | 1.9% | -5.3% | 3.5% |
| Net Margin | -1.9% | -1.9% | 0.5% | -3.6% | 2.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.54 | 1.06 | 0.78 |
| Cash Flow | |||||
| Free Cash Flow | $30.6M | $30.6M | $25.3M | $-364000.00 | $-25.6M |
| Returns | |||||
| ROE | -15.1% | -15.1% | 3.4% | -24.4% | 10.2% |
| Valuation | |||||
| EV/EBITDA | 6.64 | 6.64 | — | — | — |
| P/B | 4.22 | 4.22 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 4.6% | 4.6% | 2.5% | 16.6% | — |
| EPS Growth | -500.0% | -500.0% | 114.7% | -290.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.33 → -1.32
Residual
-40.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.